Clinical Trials
-
Principal Investigator:
Marcus Rebello Pereira, MD, MPHThis research is being done to better understand rejection in transplant recipients with HIV who receive kidneys from donors with HIV compared to donors without HIV. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC). -
Principal Investigator:
Marcus Rebello Pereira, MD, MPHThe primary objective is to evaluate long-term outcomes in transplant recipients with HIV who receive livers from donors with HIV compared to donors without HIV. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC). -
Principal Investigator:
Marcus Rebello Pereira, MD, MPHThe primary objective is to evaluate long-term outcomes in transplant recipients with HIV who receive livers from donors with HIV compared to donors without HIV. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC). -
Principal Investigator:
Magdalena E Sobieszczyk, MD, MPHThis trial is testing an experimental treatment for HIV that is called CAB + RPV LA (long-acting cabotegravir and rilpivirine). CAB + RPV LA is a combination of drugs that is used to treat HIV (called antiretroviral therapy ART). It is currently approved in the US for the treatment of people living with HIV who are taking ART and whose viral load is already undetectable. This trial is a Phase 3b study testing whether CAB + RPV LA is effective at reducing HIV viral load to undetectable levels in people who currently have a detectable viral load despite being prescribed oral ART. This trial... -
Principal Investigator:
Magdalena E Sobieszczyk, MD, MPHWe are looking for individuals over 18 years old who are interested in learning more about COVID-19 prevention research studies. We will ask you to complete a brief questionnaire to find out if you may be eligible for one of our studies. We can then schedule a phone call, teleconference, or in-person education visit so you can learn about the research we do and decide if you want to participate in one of our studies. Your responses to this questionnaire will be kept strictly confidential. -
Principal Investigator:
Magdalena E Sobieszczyk, MD, MPHDo you identify as a woman or transgender person, or do you have a non-binary gender identity? Has a medical provider ever diagnosed you with a sexually transmitted infection or recommended PrEP/another HIV prevention method? We are conducting a study to understand attitudes and preferences regarding HIV prevention methods among people who do not have HIV. The study involves taking online surveys. Some surveys are compensated. Please reach out if you are interested in hearing more about the study. -
Principal Investigator:
Deborah A Theodore, MDThis is a study for people with symptoms of long COVID. We are looking for people over the age of 18 who are interested in participating in a study to understand whether a mindfulness meditation intervention can help improve symptoms of long COVID. Study participation lasts 6 months and is fully remote. -
Principal Investigator:
Magdalena E Sobieszczyk, MD, MPHThe main purpose of this study is to look at whether experimental study drugs are safe, whether your body can handle the effects, and whether these study drugs improve the body's response to human immunodeficiency virus (HIV) in people with HIV (PWH) who started antiretroviral therapy (ART) early after getting HIV-1. The study treatments include: a treatment vaccine (not a preventative vaccine), a drug called vesatolimod (VES), and two broadly neutralizing antibodies (bNAbs; antibodies are natural proteins that the body makes in response to an infection), called GS-5423 and GS-2872. None of... -
Principal Investigator:
Magdalena E Sobieszczyk, MD, MPHThis trial is testing two experimental drugs for HIV called VH3810109 (also called N6LS) and Fostemsavir (FTR). This trial is a Phase 1b study testing whether these drugs are safe to use in people and can be taken comfortably, as well as whether they may be helpful in eliminating HIV from the body. In this study, FTR will be given as a "helper drug" in addition to VH3810109. We think that, given together with VH3810109, it may help the immune system better recognize and kill cells with hidden HIV, thereby reducing the HIV in "reservoirs" within the body. You may be eligible for this study if...